Compare WAFDP & CGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | WAFDP | CGEN |
|---|---|---|
| Founded | N/A | 1993 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | N/A | 191.1M |
| IPO Year | 1996 | 2001 |
| Metric | WAFDP | CGEN |
|---|---|---|
| Price | $16.40 | $2.47 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $5.00 |
| AVG Volume (30 Days) | 11.8K | ★ 300.0K |
| Earning Date | N/A | 05-18-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 5.20 | N/A |
| EPS | ★ 2.45 | N/A |
| Revenue | ★ $29,650,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $75.09 |
| P/E Ratio | $6.71 | ★ N/A |
| Revenue Growth | ★ 7.79 | N/A |
| 52 Week Low | $15.94 | $1.30 |
| 52 Week High | $17.49 | $3.24 |
| Indicator | WAFDP | CGEN |
|---|---|---|
| Relative Strength Index (RSI) | 42.45 | 46.09 |
| Support Level | $16.34 | $2.23 |
| Resistance Level | $16.67 | $2.54 |
| Average True Range (ATR) | 0.15 | 0.12 |
| MACD | -0.02 | -0.03 |
| Stochastic Oscillator | 14.06 | 4.04 |
WaFd Inc is engaged in providing lending, depository, insurance, and other banking services to consumers, mid-sized to large businesses, and owners and developers of commercial real estate. Through the WaFd Bank, it is involved in accepting deposits from the general public and investing these funds in loans of various types, including first-lien mortgages on single-family dwellings, construction loans, land acquisition and development loans among others. The Bank also invests in certain United States government and agency obligations along with other investments and also performs insurance brokerage activities. Geographically, it operates in Washington, Oregon, Idaho, Arizona, Utah, Nevada, New Mexico, California and Texas.
Compugen Ltd is a clinical-stage therapeutic discovery and development company utilizing Unigen, its AI/ML-powered computational discovery capabilities, to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Its immuno-oncology pipeline consists of four clinical-stage programs: COM701, COM902, rilvegostomig, and GS-0321 (previously COM503), targeting immune checkpoints the company discovered computationally. The company's revenues are generated mainly from collaborative and license agreements. Geographically, it generates maximum revenue from the United Kingdom, and the rest from the United States.